WEBSITE BSE:0 NSE: Inc. Year: 2023 Industry: Hospital & Healthcare Services My Bucket: Add Stock
Last updated: 15:58
No Notes Added Yet
Invicta Diagnostic Ltd. is a Mumbai-based healthcare services company that operates a network of diagnostic centres under the brand PC Diagnostics, offering a wide range of pathology and radiology testing services across the Mumbai Metropolitan Region. Incorporated in 2021 and later converted to a public limited company, it follows a hub-and-spoke model with a flagship centre in Thane West equipped for advanced imaging such as PET-CT and MRI, several other hubs for specialised diagnostics, and smaller spoke units for basic imaging and sample co...Read More
Invicta Diagnostic Ltd. is a Mumbai-based healthcare services company that operates a network of diagnostic centres under the brand PC Diagnostics, offering a wide range of pathology and radiology testing services across the Mumbai Metropolitan Region. Incorporated in 2021 and later converted to a public limited company, it follows a hub-and-spoke model with a flagship centre in Thane West equipped for advanced imaging such as PET-CT and MRI, several other hubs for specialised diagnostics, and smaller spoke units for basic imaging and sample collection, supported by a central laboratory. The company’s comprehensive service portfolio includes routine and specialised pathology tests alongside basic and advanced radiology procedures, catering primarily to walk-in individual patients as well as institutional clients. In December 2025, Invicta Diagnostic launched a ₹28.12 crore SME initial public offering (IPO) on the NSE Emerge platform to fund the establishment of additional diagnostic centres and general corporate needs, and its shares debuted at a healthy premium, reflecting solid market interest. ...Read Less
Our experts help you choose the right stocks based on performance, risk, and growth potential.
Market Cap ₹129 Cr.
Stock P/E 26.2
P/B 6.9
Current Price ₹102.8
Book Value ₹ 14.9
Face Value 10
52W High ₹105
Dividend Yield 0%
52W Low ₹ 58.1
Price goes above X
Price falls below X
PE goes above X
PE falls below X
₹ | |
| #(Fig in Cr.) |
|---|
| Net Sales |
| Other Income |
| Total Income |
| Total Expenditure |
| Operating Profit |
| Interest |
| Depreciation |
| Exceptional Income / Expenses |
| Profit Before Tax |
| Provision for Tax |
| Profit After Tax |
| Adjustments |
| Profit After Adjustments |
| Adjusted Earnings Per Share |
| #(Fig in Cr.) | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|
| Net Sales | 16 | 30 | |
| Other Income | 0 | 0 | |
| Total Income | 16 | 30 | |
| Total Expenditure | 9 | 21 | |
| Operating Profit | 7 | 9 | |
| Interest | 0 | 0 | |
| Depreciation | 2 | 2 | |
| Exceptional Income / Expenses | 0 | 0 | |
| Profit Before Tax | 5 | 7 | |
| Provision for Tax | 1 | 2 | |
| Profit After Tax | 4 | 5 | |
| Adjustments | -0 | -0 | |
| Profit After Adjustments | 4 | 5 | |
| Adjusted Earnings Per Share | 4.5 | 5.8 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | 88% | 0% | 0% | 0% |
| Operating Profit CAGR | 29% | 0% | 0% | 0% |
| PAT CAGR | 25% | 0% | 0% | 0% |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Share Price CAGR | NA% | NA% | NA% | NA% |
| ROE Average | 40% | 40% | 40% | 40% |
| ROCE Average | 43% | 41% | 41% | 41% |
| #(Fig in Cr.) | Mar 2024 | Mar 2025 |
|---|---|---|
| Shareholder's Funds | 10 | 15 |
| Minority's Interest | -1 | -1 |
| Borrowings | 4 | 4 |
| Other Non-Current Liabilities | 1 | 1 |
| Total Current Liabilities | 2 | 3 |
| Total Liabilities | 16 | 21 |
| Fixed Assets | 12 | 10 |
| Other Non-Current Assets | 0 | 5 |
| Total Current Assets | 4 | 6 |
| Total Assets | 16 | 21 |
| #(Fig in Cr.) | Mar 2024 | Mar 2025 |
|---|---|---|
| Opening Cash & Cash Equivalents | 0 | 1 |
| Cash Flow from Operating Activities | 6 | 7 |
| Cash Flow from Investing Activities | -9 | -5 |
| Cash Flow from Financing Activities | 4 | -1 |
| Net Cash Inflow / Outflow | 1 | 1 |
| Closing Cash & Cash Equivalent | 1 | 2 |
| # | Mar 2024 | Mar 2025 |
|---|---|---|
| Earnings Per Share (Rs) | 4.47 | 5.81 |
| CEPS(Rs) | 6.82 | 8.82 |
| DPS(Rs) | 0 | 0 |
| Book NAV/Share(Rs) | 11.57 | 17.37 |
| Core EBITDA Margin(%) | 44.77 | 30.57 |
| EBIT Margin(%) | 32.99 | 22.57 |
| Pre Tax Margin(%) | 32.35 | 21.81 |
| PAT Margin (%) | 24.04 | 16.38 |
| Cash Profit Margin (%) | 36.25 | 24.66 |
| ROA(%) | 23.95 | 26.57 |
| ROE(%) | 39.1 | 40.48 |
| ROCE(%) | 38.55 | 42.85 |
| Receivable days | 19.71 | 14.01 |
| Inventory Days | 9.08 | 5.44 |
| Payable days | -1344.36 | -3135.74 |
| PER(x) | 0 | 0 |
| Price/Book(x) | 0 | 0 |
| Dividend Yield(%) | 0 | 0 |
| EV/Net Sales(x) | 0.16 | 0.33 |
| EV/Core EBITDA(x) | 0.36 | 1.05 |
| Net Sales Growth(%) | 0 | 90.11 |
| EBIT Growth(%) | 0 | 30.11 |
| PAT Growth(%) | 0 | 29.54 |
| EPS Growth(%) | 0 | 30.01 |
| Debt/Equity(x) | 0.39 | 0.24 |
| Current Ratio(x) | 1.62 | 2.37 |
| Quick Ratio(x) | 1.45 | 2.18 |
| Interest Cover(x) | 51.8 | 29.51 |
| Total Debt/Mcap(x) | 0 | 0 |
| # | Mar 2026 |
|---|---|
| Promoter | 66.7 |
| FII | 4.2 |
| DII | 4.3 |
| Public | 24.81 |
| Others | 0 |
| Total | 100 |
| # | Mar 2026 |
|---|---|
| Promoter | 0.84 |
| FII | 0.05 |
| DII | 0.05 |
| Public | 0.31 |
| Others | 0 |
| Total | 1.26 |
* The pros and cons are machine generated.
You May Also Know About
Looking to buy unlisted shares or need guidance on the investment process? Our expert Private Equity Advisors are here to assist you with accurate information, real-time pricing, and seamless execution.
Want to sell unlisted shares, liquidate your ESOPs, or understand the step-by-step process of liquidation? Connect with our Buying Team for smooth coordination, quick evaluations, and end-to-end support.
Planning to build or grow your portfolio? For Mutual Fund investments, PMS solutions, tailored portfolio creation, and overall wealth management, our dedicated Wealth Team is ready to guide you.
ChatGPT
Claude
Perplexity
